Table 3.

The effects of Hyperoside pre-treatment on clinical and metabolic parameters of db/db mice.

Index	db/m	db/db	db/db +HHPS	db/db +LHPS
BW(g)	25.38 ± 2.68	59.18 ± 2.60##	44.66 ± 8.39**	47.14 ± 9.67*
UACR (mg/g)	8.93 ± 4.14	290.33 ± 73.20##	129.61 ± 45.85**	121.89 ± 65.09**
FBG (mmol/L)	6.27 ± 0.98	33.22 ± 0.08##	28.53 ± 4.31**	29.41 ± 2.42*
TC (mmol/L)	2.15 ± 0.36	5.12 ± 4.22##	3.49 ± 3.32*	3.74 ± 3.51*
TG (mmol/L)	1.37 ± 0.95	1.62 ± 0.81	1.97 ± 0.85	1.95 ± 0.74
LDL-C (mmol/L)	0.20 ± 0.05	0.37 ± 0.09##	0.25 ± 0.07*	0.19 ± 0.07**
HDL-C(mmol/L)	1.08 ± .0.21	1.99 ± 0.42	1.90 ± 0.39	1.97 ± 0.47
BUN (mmol/L)	9.89 ± 2.21	9.42 ± 1.96	8.51 ± 1.86	8.61 ± 1.85
SCr (μmol/L)	10.00 ± 1.90	8.40 ± 3.36	9.38 ± 2.07	8.50 ± 3.30
UA (μmol/L)	224.30 ± 64.48	317.40 ± 97.57#	352.25 ± 64.67	376.50 ± 75.92
ALB (g/L)	42.12 ± 3.14	46.04 ± 8.51	44.23 ± 8.49	45.18 ± 2.38

db/m: normal mice; db/db: treated with vehicle solution; LHPS and HHPS: db/db mice were treated with 40 or 80 mg/kg/d Hyperoside for 12 weeks after DM establishment respectively. Data are presented as mean ± SD. n=6-7. ^#P < 0.05 vs db/m mice; ^##P < 0.01 vs db/m mice; *P < 0.05 vs db/db mice; **P < 0.01 vs db/db mice.

BW, body weight; UACR, urine albumin creatine ratio; FBG, fasting blood glucose; TC, total cholesterol; TG, Triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; BUN, blood urea nitrogen; SCr, serum creatinine; UA, uric acid; ALB, serum albumin.